Practices & Lifestyle
Full-Body MRI Screening — Prenuvo, Ezra, Q Bio, and the Incidentaloma Problem
Per 1,000 asymptomatic adults screened with WB-MRI: ~950 abnormal findings, ~15-20 cancers, ~30% trigger workup. Zero RCT mortality evidence. ACR does not recommend for average-risk adults. Vanguard's read on Prenuvo, Ezra, Q Bio.
Galleri — The Multi-Cancer Early Detection Blood Test, and What the 2026 Data Actually Shows
The NHS-Galleri trial missed its primary endpoint at ASCO 2026. High specificity (~99.6%) and PPV (52-62%), modest sensitivity (~30-40% all cancers), zero mortality data. $949 cash pay. No FDA approval as screening. Vanguard's read on the largest multi-cancer detection trial to date.